Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
出版年份 2019 全文链接
标题
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
作者
关键词
Sodium–glucose co-transporter 2 inhibitors, Cardiovascular disease, Heart failure, Real-world data
出版物
Cardiovascular Diabetology
Volume 18, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-09-24
DOI
10.1186/s12933-019-0919-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
- (2019) David Fitchett et al. CIRCULATION
- Heart failure and type 2 diabetes: From CVOTs, with hope
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- Cardiovascular outcome trials of glucose-lowering medications: an update
- (2019) Philip Home DIABETOLOGIA
- The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan
- (2019) Shih-Chieh Shao et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- (2019) Jennifer R Donnan et al. BMJ Open
- ASSOCIATION OF GLYCEMIC VARIABILITY WITH LEFT VENTRICULAR DIASTOLIC FUNCTION IN TYPE 2 DIABETES MELLITUS
- (2019) Shun Yokota et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial
- (2019) Remo H. M. Furtado et al. CIRCULATION
- Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
- (2019) Giovanni Musso et al. BMJ-British Medical Journal
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
- (2018) Atsushi Tanaka et al. Cardiovascular Diabetology
- Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
- (2018) Sarayut Lahnwong et al. Cardiovascular Diabetology
- SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
- (2018) M. V. Karg et al. Cardiovascular Diabetology
- Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England
- (2018) Adrian H. Heald et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
- (2018) Man Guo et al. DIABETES OBESITY & METABOLISM
- Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
- (2018) Bernard Zinman et al. DIABETOLOGIA
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
- (2018) Agostino Consoli et al. Expert Opinion On Drug Safety
- Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease
- (2018) Shyue-Luen Chang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
- (2018) Tricia Santos Cavaiola et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
- (2018) Fumitaka Soga et al. Cardiovascular Diabetology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
- (2018) Lindsay E. Clegg et al. DIABETES CARE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Visit-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease
- (2017) Jianqi Wang et al. JOURNAL OF HYPERTENSION
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Association of In-Hospital Mortality and Dysglycemia in Septic Patients
- (2017) Hsiao-Yun Chao et al. PLoS One
- Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
- (2016) Subodh Verma et al. DIABETES CARE
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
- (2016) Atsuo Tahara et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality
- (2015) Paul Muntner et al. ANNALS OF INTERNAL MEDICINE
- Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study
- (2015) S. Sha et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan
- (2014) Ching-Lan Cheng et al. JOURNAL OF EPIDEMIOLOGY
- Prespecified Falsification End Points
- (2013) Vinay Prasad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes
- (2013) Yujie Wang et al. KIDNEY INTERNATIONAL
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Negative Controls
- (2010) Marc Lipsitch et al. EPIDEMIOLOGY
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Validation of the national health insurance research database with ischemic stroke cases in Taiwan
- (2010) Ching-Lan Cheng et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More